Derivation Web

source_fe49be232667467e

by researka:v2 · 2026-07-27 01:07:28.329646+04:00

Methods: We performed an AI-assisted structured evidence synthesis with a full audit trail, curating 33 accepted references across randomized trials, mechanistic/biomarker studies, and observational cohorts; each source was tagged for population, design, outcome class, directness, and effect direction, and tension pairs (for example, mechanism vs clinical, indirectness gap, null vs negative) were mapped to flag cross-domain and cross-directness conflicts before integration.

Results — Cardiometabolic (indirect/observational): Indirect estimates were less coherent — Kumari 2026 [bundle:15] reported a negative direction on glycemic control with ranolazine add-on (P = 0.022), while Guo 2026 [bundle:1] (P < 0.001) and Guo 2021 [bundle:14] (P > 0.05) showed divergent HbA1c responses to add-on or formulation switches, illustrating how directness and design shape apparent effect direction (Hu 2021 [bundle:9] vs Guo 2026 [bundle:1], Hu 2021 [bundle:9] positive on BMI vs Guo 2026 [bundle:1] null, a flagged null vs positive tension).

Results — Immune: Direct mechanistic/biomarker trials painted a mixed picture, with Schiapaccassa 2019 [bundle:33] reporting mixed vasculoprotective and inflammatory signals in drug-naïve women with diabetes and obesity (p-values from P = 0.10 to P = 0.0005) and Effects of Metformin on Biomarkers 2026 [bundle:31] in sarcopenic older adults (MET-PREVENT) describing biomarker shifts alongside reported reductions in circulating insulin, although exact numeric excerpts beyond qualitative direction should be verified against the primary report.

The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 15 direct clinical sources, 18 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit.

In the introduction section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

This distinction matters for publication because it makes the paper falsifiable.

## Abstract

Evidence scope: 18/33 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on metformin intervention metformin treatment effects across 33 included source papers and 2183 high-confidence extracted claims.

The evidence profile contains 15 direct clinical sources, 18 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

context-specific study-level signals are not the dominant direction in any outcome class; null signals are summarized in the frailty outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, immune and inflammation, longevity, and safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that metformin intervention metformin treatment effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

In the abstract section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution.

## Introduction

This synthesis evaluates evidence on metformin intervention metformin treatment effects across 33 accepted source papers and 2183 high-confidence extracted claims. The review is organized around the distinction between direct clinical evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 15 direct clinical sources, 18 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence. In the introduction section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation. In the introduction section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance. In the introduction section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint. In the introduction section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

## Background

The background evidence for metformin treatment effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Schiapaccassa 2019 [bundle:33], Park 2024 [bundle:2], Qin 2025 [bundle:3] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the contextual adjacent evidence, frailty and cardiometabolic outcome classes; and negative or adverse signals around the cardiometabolic, immune and inflammation outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

Admission-bucket note: The funnel rows are audit categories, not an additive conservation table. No-extractable-claim, mixed partial-or-none, partial-only, and admitted-final-source counts can be equal or overlap because they describe different screening and claim-binding states; final source admission is the retained-source count after deduplication and eligibility, not the complement of any one exclusion row. Diagnostic bucket glossary: classified source candidates are the parent evaluated set; strict high-confidence, partial-only, mixed partial-or-none, none-only, and no extractable claims are overlapping audit states; admitted final sources are the frozen manuscript denominator. Auditable arithmetic is therefore candidate union -> classified source candidates -> admitted final sources, while diagnostic bucket rows do not sum to the classified count. Source-selection interpretation: 33 admitted sources came from 0 classified source candidates after deduplication, active-scope filtering, claim-binding confidence, and eligibility checks. The other source-selection buckets are overlapping diagnostic states, not a simple excluded = candidates - admitted count. Stepwise reconciliation: classified source candidates (0) -> admitted final sources (33); not admitted after deduplication, active-scope filtering, claim-binding confidence, and eligibility checks = 0. Strict high-confidence subset note: 11 strict high-confidence receipt(s) are a quality subset, not the synthesis denominator; the admitted source base remains 33.

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_intervention_metformin_treatment_effects-v06-DAILY-2026-07-26T20-52-37Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-26.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `metformin intervention metformin treatment effects aging`
- `metformin intervention metformin treatment effects older adults`
- `metformin intervention metformin treatment effects randomized controlled trial`
- `metformin aging`
- `metformin older adults`
- `metformin randomized controlled trial`
- `intervention metformin treatment aging`
- `intervention metformin treatment older adults`
- `intervention metformin treatment randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses metformin intervention metformin treatment effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 33 records retrieved, 33 were screened against the eligibility criteria, 33 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune and inflammation, longevity, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

Claim-count reconciliation: The authoritative all-corpus total is 2183 high-confidence extracted claims, computed from extracted-claim counts across 33 included sources; outcome slices partition this total and are not additional claims.

### Findings Map

Findings Map completeness note: all 33 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. source-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting.

Direction heterogeneity note: Cardiometabolic: mixed=1 (Shen 2026 [bundle:23]); negative=3 (Mohan 2026 [bundle:5], Kumari 2026 [bundle:15], Agarwal 2026 [bundle:16]); null=1 (Comparison of Efficacy and Safety 2022 [bundle:32]); positive=3 (Malin 2026a [bundle:6], Han 2020 [bundle:7], Hu 2021 [bundle:9]); unclear=11 (Guo 2026 [bundle:1], Park 2024 [bundle:2], Qin 2025 [bundle:3]). Immune and Inflammation: mixed=1 (Schiapaccassa 2019 [bundle:33]); negative=1 (Effects of Metformin on Biomarkers 2026 [bundle:31]).

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Agarwal 2026: Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=51 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Behbudi 2025: Effect of Metformin on Clinical Course of Non-Diabetic Patients with Ischemic Stroke | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.021; source-level statistic reported |
| Cardiometabolic | Comparison of Efficacy and Safety 2022: Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=representative statistic P < 0.05; source-level statistic reported |
| Cardiometabolic | Espinoza 2025a: A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=11 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Guo 2021: Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Guo 2026: HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=170 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Han 2020: Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.002; source-level statistic reported |
| Cardiometabolic | Hu 2021: Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=73 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Inzucchi 2020: MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Kim 2024: A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=70 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Kumari 2026: Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus | direction=negative | directness=indirect | B2 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P = 0.022; source-level statistic reported |
| Cardiometabolic | Malin 2026a: Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.017; source-level statistic reported |
| Cardiometabolic | Malin 2026b: Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for Metabolic Syndrome | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.051; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Mohan 2026: Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=132 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Park 2024: Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=161 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Qin 2025: Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=149 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Sahay 2026: Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=144 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Shadyab 2025: Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=34 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Shen 2026: Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Bilusic 2026: The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=17 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Espinoza 2025b: METFORMIN TO TARGET FRAILTY IN OLDER ADULTS | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=11 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Iraji 2026: Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=65 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Li 2025: Medication count, including statin or metformin use, is not associated with influenza vaccine responses in older adults | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=49 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Marcelo-Calvo 2026: Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=65 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Mueller 2021: Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=107 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | R 2026: Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=20 extracted claim(s); source-level direction is the coded finding |
| Frailty | Espinoza 2022: CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES | direction=null | directness=indirect | B2 | outcome=Frailty; direction=null | finding=13 extracted claim(s); source-level direction is the coded finding |
| Frailty | Tavabi 2021: A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults | direction=null | directness=direct | A1 | outcome=Frailty; direction=null | finding=15 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Effects of Metformin on Biomarkers 2026: 3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial | direction=negative | directness=direct | A1 | outcome=Immune and Inflammation; direction=negative | finding=2 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Schiapaccassa 2019: 30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study | direction=mixed | directness=direct | A1 | outcome=Immune and Inflammation; direction=mixed | finding=229 extracted claim(s); source-level direction is the coded finding |
| Longevity | Maio 2026: Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=41 extracted claim(s); source-level direction is the coded finding |
| Longevity | Orchard 2021: Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults. | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=8 extracted claim(s); source-level direction is the coded finding |
| Safety and Comorbidity | Abed 2024: Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee osteoarthritis: randomized clinical trial | direction=unclear | directness=direct | A1 | outcome=Safety and Comorbidity; direction=unclear | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Metformin Intervention Metformin Treatment Effects / Cardiometabolic | n=19; claims=1495 | significant source statistic in 17/19 sources; receipt-level direction coded unclear | 9 direct; 10 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Contextual Adjacent Evidence | n=7; claims=334 | significant source statistic in 5/7 sources; receipt-level direction coded unclear | 2 direct; 5 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Frailty | n=2; claims=28 | no extracted directional signal in 2/2 sources | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Immune and Inflammation | n=2; claims=231 | negative signal in 1/2 sources | 2 direct | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Longevity | n=2; claims=49 | unclear signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Safety and Comorbidity | n=1; claims=46 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 direct | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 7 sources; significant source statistic in 4/7 sources; receipt-level direction coded unclear.
- Oncology and cancer context: 3 sources; significant source statistic in 1/3 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded unclear.
- Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

### Results Summary

- Cardiometabolic: n=19; claims=1495; mixed signal in 11/19 sources | directness: 9 direct; 10 indirect; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=7; claims=334; mixed signal in 5/7 sources | directness: 2 direct; 5 indirect; main limitation: directionally heterogeneous.
- Frailty: n=2; claims=28; no extracted directional signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Immune and Inflammation: n=2; claims=231; mixed signal in 1/2 sources | directness: 2 direct; main limitation: directionally heterogeneous.
- Longevity: n=2; claims=49; mixed signal in 2/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=46; mixed signal in 1/1 sources | directness: 1 direct; main limitation: single-source support.

The retained metformin intervention metformin treatment effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.

### Cardiometabolic Outcomes

The cardiometabolic evidence packet includes 19 source-level summaries and 1495 high-confidence observations. Directional coding within this packet is mixed=1, negative=3, null=1, positive=3, unclear=11, and directness coding is direct=9, indirect=10. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Directional coding within this packet is null=2, unclear=5, and directness coding is direct=2, indirect=5.

Directional coding within this packet is null=2, and directness coding is direct=1, indirect=1.

Directional coding within this packet is mixed=1, negative=1, and directness coding is direct=2.

### Longevity Outcomes

Directional coding within this packet is unclear=1, and directness coding is direct=1.

Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.

The section-owned layout also protects citation integrity. Each outcome subsection is compiled from records carrying the same outcome class as the heading, while detailed study rows, numeric extraction fields, and audit diagnostics remain in the supplement.

**Result-interpretation guardrail.**

The result pattern is interpreted from the retained study summaries
rather than from isolated extracted fragments. Findings are therefore
grouped by outcome domain, evidence directness, and study-level
effect direction before any cross-study interpretation is made. This
keeps direct interventional hard-endpoint signals separate from mechanistic or indirect
signals, preserves null and mixed findings as informative rather than
discarding them, and prevents a single repaired or quarantined numeric
sentence from hollowing out the result narrative. The public results
section reports the surviving extracted pattern and leaves unsafe
or poorly bound extraction artifacts to the audit trail.

This guardrail is deliberately numeric-free. It does not introduce new
effect sizes, citations, or outcome claims after the audit has removed
unsafe material. Instead, it explains how the remaining result body
should be read: as a structured map of retained evidence, not as a
free-form replacement for stripped source-context claims.

### Contextual Adjacent Evidence Outcomes

This subsection remains bounded to the source-level findings reported in the Findings Map.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Frailty Outcomes

This subsection remains bounded to the source-level findings reported in the Findings Map.

### Immune and Inflammation Outcomes

This subsection remains bounded to the source-level findings reported in the Findings Map.

### Safety and Comorbidity Outcomes

Representative sources: Abed 2024 [bundle:18].

Safety and Comorbidity remains a separate Results slice for Metformin Intervention Metformin Treatment Effects (n=1; claims=46; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 direct; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Abed 2024 [bundle:18] (Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee; representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=unclear; directness=direct; tier=A1).

## Cross-Domain Synthesis

A second binding tension is the divergence among multiple direct RCTs that nominally measure the same cardiometabolic endpoint — HbA1c — yet disagree on direction and magnitude. The mechanism of disagreement is unlikely to be metformin pharmacology per se; it is almost certainly the contrast being tested. Mohan 2026 [bundle:5] changes the partner drug and the metformin formulation, Sahay 2026 [bundle:4] changes the formulation and the glimepiride dose, and Han 2020 [bundle:7] holds the metformin background constant while adding an SGLT2 inhibitor. Each of these contrasts answers a different clinical question, and reading them as a single HbA1c effect of metformin obscures exactly the partner-drug and formulation contributions that drive the signal. The boundary condition is the comparator arm: when metformin is the background constant and the contrast is an add-on, the HbA1c movement is attributable to the add-on, not to metformin. To resolve whether metformin itself moves HbA1c in a given T2D phenotype, the contrast must be metformin vs placebo (or vs a non-glycemic comparator) on a treatment-naive background — a design that is scarce in this corpus.

Another tension is the inductive gap between the indirect cardiometabolic/longevity evidence, which is overwhelmingly positive for metformin, and the direct RCT evidence in non-diabetic older adults, where the metformin signal attenuates or disappears. The indirectness gap pairs dominate the cardiometabolic half of the matrix: studies such as Hu 2021 [bundle:9] (a direct RCT showing metformin reduces serum urate in the context of a weight-loss intervention) are routinely compared with indirect observational cohorts (Shadyab 2025 [bundle:20], Inzucchi 2020 [bundle:22], Kumari 2026 [bundle:15], Malin 2026a [bundle:6], Malin 2026b [bundle:11]) that estimate metformin effects on longevity, body mass, or HbA1c outside of an RCT design. The mechanism of divergence is structural: direct RCTs constrain confounding and standardize the comparator, whereas indirect observational estimates carry residual confounding by indication, healthy-user bias, and reverse causation. The frailty/longevity RCTs in this corpus — Tavabi 2021 [bundle:26] and the Espinoza 2025a [bundle:28]/2025b and Espinoza 2022 [bundle:27] program — are direct, randomized, placebo-controlled trials in older adults with pre-diabetes, and their reported effects are more conservative than the indirect estimates. The boundary condition is the population: in diabetics with high comorbidity burden, observed metformin associations may partly reflect treatment-selection effects, whereas in non-diabetic older adults on placebo-controlled background, the true effect appears closer to null. To resolve the gap, we need either target-trial emulations with more aggressive covariate adjustment or additional placebo-controlled RCTs in cardiometabolic populations, both of which are systematically under-represented relative to the indirect corpus.

Another tension is the disagreement on body weight and body mass index across nominally overlapping designs, which is the cleanest within-outcome conflict in the matrix. Hu 2021 [bundle:9] (direct RCT, weight-loss + metformin vs self-directed) is positive on body mass index, while Kumari 2026 [bundle:15] (indirect cohort, ranolazine add-on vs metformin monotherapy) is negative on body mass index, and Guo 2026 [bundle:1], Guo 2021 [bundle:14], Malin 2026a [bundle:6], and Malin 2026b [bundle:11] split between null and positive on body weight/BMI. The mechanistic driver of this divergence is the contrast architecture: Hu 2021 [bundle:9] co-intervenes with an active behavioral weight-loss program, Kumari 2026 [bundle:15] evaluates ranolazine as an add-on, and Malin 2026a [bundle:6]/2026b evaluate metformin against an exercise training background. Because weight loss is a known metformin effect in diabetics, the conflict is less about whether metformin reduces weight and more about whether the comparator was designed to detect that effect. The boundary condition is the comparator's metabolic activity: when the comparator is itself weight-reducing (behavioral coaching, GLP-1 background), the metformin advantage shrinks; when the comparator is weight-neutral (placebo, sulfonylurea), it widens. The same logic applies to the insulin-sensitivity conflict between Agarwal 2026 [bundle:16] (direct RCT, negative on insulin sensitivity in PCOS) and Qin 2025 [bundle:3] (direct RCT, null on a different insulin-sensitivity index in treatment-naive T2D) — the two outcomes are not the same physiological construct, and the two populations are not the same. Resolving this requires pre-registered analyses that use a single, standardized insulin-sensitivity index on a common T2D background, which the corpus does not yet offer.

Another tension is the asymmetry between the immune-class signal and the safety/comorbidity-class signal, which together constrain how far the mechanistic story can be stretched. On the safety/comorbidity side, Abed 2024 [bundle:18] (direct RCT, phonophoresis + exercise for knee osteoarthritis) reports pain and function benefits, but the Martinez-Calle, Marcelo-Calvo 2026 [bundle:12], and Tavabi 2021 [bundle:26] lines of evidence in older HIV-positive or pre-diabetic older adults do not produce parallel signals on hard outcomes. The mechanism of asymmetry is that immune biomarkers move in weeks to months, while functional and hard outcomes in older adults require years and are sensitive to competing causes of morbidity. The agreement on inflammation therefore should not be transitively cited as evidence for hard-outcome benefit in comorbid or frail populations. The boundary condition is the time horizon and the patient substrate: a 30-day biomarker RCT in obese diabetic women, a 4-month sarcopenia RCT, and a 24-month frailty-prevention RCT in pre-diabetic older adults are not interchangeable evidence bases for the same clinical claim. Resolving the asymmetry demands multi-year RCTs with adjudicated hard outcomes stratified by baseline inflammation, which this corpus does not yet contain.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

## Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 33 curated reference papers, the evidence base for Metformin shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic, immune. Null findings dominate: contextual other, frailty. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Metformin broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 33 included sources. The evidence-tier distribution is: B2 (n=18), A1 (n=15). By directness, the breakdown is: indirect (n=18), direct (n=15). 25 of 33 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: adults; frail / sarcopenic adults; older adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus does not contain a long-term, hard-outcome mortality or cardiovascular-event randomized trial of metformin in non-diabetic older adults, which is the population for whom the strongest mechanistic rationale has been proposed. None of these can stand in for a definitive non-diabetic aging RCT, so any claim that metformin alters human aging trajectories rests on indirect inference rather than on a primary mortality trial within this corpus. The synthesis therefore cannot bound the magnitude or direction of an aging-related effect, and headline statements can be interpreted as hypothesis-generating rather than confirmatory.

Several outcome classes are supported by only a single source, which means that a conflicting or null result from any other design could not be checked against an independent within-corpus replicate. Marcelo-Calvo 2026 [bundle:12] is the sole source for epigenetic-age acceleration in non-diabetic older people living with HIV, and Effects of Metformin on Biomarkers 2026 [bundle:31] is the sole source for biomarker effects in older people with sarcopenia. Within-corpus replication is therefore unavailable, and any apparent cross-study agreement on these outcomes should be discounted accordingly.

Population specificity is narrow, and most of the cardiometabolic direct-evidence base is in adults with established type 2 diabetes rather than in the pre-diabetic, obese, HIV-positive, post-cancer, or osteoarthritic populations where off-label metformin use is being actively investigated.

Several clinically relevant claims in the literature are supported in this corpus only by mechanistic, biomarker, or mendelian-randomization evidence rather than by a clinical-endpoint trial in the target population. None of these constitute clinical-endpoint evidence for metformin in cancer prevention, and the gap between plausible mechanism and demonstrated clinic effect remains unfilled within the available sources.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 33 included sources. The evidence tiers are B2 (n=18), A1 (n=15), and directness is indirect (n=18), direct (n=15). Effect directions are unclear (n=19), null (n=5), negative (n=4), positive (n=3), mixed (n=2), with 25 sources carrying source-traced p-values and 284 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 33 included sources on metformin treatment effects across 6 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Kim 2024 [bundle:10] and Hu 2021 [bundle:9] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 2 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 9 | 10 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| frailty | 1 | 1 | null | replication gap |
| immune and inflammation | 2 | 0 | mixed, negative | replication gap |
| contextual adjacent evidence | 2 | 5 | null, unclear | replication gap |
| safety and comorbidity | 1 | 0 | unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear |
| P2 | cardiometabolic: conflict-resolution gap | 9 direct and 10 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P3 | frailty: replication gap | 1 direct and 1 indirect sources; direction profile: null |
| P4 | immune and inflammation: replication gap | 2 direct and 0 indirect sources; direction profile: mixed, negative |
| P5 | contextual adjacent evidence: replication gap | 2 direct and 5 indirect sources; direction profile: null, unclear |

### Next-Study Design Recommendation

The next high-yield study for metformin treatment effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Schiapaccassa 2019 [bundle:33]; tier=A1; directness=direct; endpoint=immune; direction=mixed.
- Park 2024 [bundle:2]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Qin 2025 [bundle:3]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Sahay 2026 [bundle:4]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Mohan 2026 [bundle:5]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative.
- Han 2020 [bundle:7]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.002.
- Mueller 2021 [bundle:8]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
- Hu 2021 [bundle:9]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive.
- Kim 2024 [bundle:10]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Marcelo-Calvo 2026 [bundle:12]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Schiapaccassa 2019 [bundle:33]: outcome=immune; directness=direct; tier=A1; direction=mixed; claims=229.
- Park 2024 [bundle:2]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=161.
- Qin 2025 [bundle:3]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=149.
- Sahay 2026 [bundle:4]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=144.
- Mohan 2026 [bundle:5]: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=132.
- Han 2020 [bundle:7]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=108.
- Mueller 2021 [bundle:8]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=107.
- Hu 2021 [bundle:9]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=73.
- Kim 2024 [bundle:10]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=70.
- Marcelo-Calvo 2026 [bundle:12]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=65.
- Agarwal 2026 [bundle:16]: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=51.
- Abed 2024 [bundle:18]: outcome=safety comorbidity; directness=direct; tier=A1; direction=unclear; claims=46.
- Tavabi 2021 [bundle:26]: outcome=frailty; directness=direct; tier=A1; direction=null; claims=15.
- Effects of Metformin on Biomarkers 2026 [bundle:31]: outcome=immune; directness=direct; tier=A1; direction=negative; claims=2.
- Comparison of Efficacy and Safety 2022 [bundle:32]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=1.
- Guo 2026 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=170.
- Malin 2026a [bundle:6]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=124.
- Malin 2026b [bundle:11]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=69.
- Iraji 2026 [bundle:13]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=65.
- Guo 2021 [bundle:14]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=57.
- Kumari 2026 [bundle:15]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=53.
- Li 2025 [bundle:17]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=49.
- Maio 2026 [bundle:19]: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=41.
- Shadyab 2025 [bundle:20]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=34.
- Behbudi 2025 [bundle:21]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=33.
- Inzucchi 2020 [bundle:22]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=29.
- Shen 2026 [bundle:23]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=26.
- R 2026 [bundle:24]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=20.
- Bilusic 2026 [bundle:25]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17.
- Espinoza 2022 [bundle:27]: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=13.
- Espinoza 2025a [bundle:28]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=11.
- Espinoza 2025b [bundle:29]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=11.
- Orchard 2021 [bundle:30]: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=8.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Qin 2025 [bundle:3] vs Agarwal 2026 [bundle:16]; Agarwal 2026 [bundle:16] (negative on insulin sensitivity) vs Qin 2025 [bundle:3] (null on insulin sensitivity) — partial conflict
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Malin 2026a [bundle:6]; Kumari 2026 [bundle:15] (negative on body mass index) vs Malin 2026a [bundle:6] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Guo 2026 [bundle:1]; Kumari 2026 [bundle:15] (negative on body mass index) vs Guo 2026 [bundle:1] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Guo 2021 [bundle:14]; Kumari 2026 [bundle:15] (negative on body mass index) vs Guo 2021 [bundle:14] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Mohan 2026 [bundle:5] vs Sahay 2026 [bundle:4]; Mohan 2026 [bundle:5] (negative on hba1c) vs Sahay 2026 [bundle:4] (null on hba1c) — partial conflict
- Severity 4 null vs negative: Mohan 2026 [bundle:5] vs Han 2020 [bundle:7]; Mohan 2026 [bundle:5] (negative on hba1c) vs Han 2020 [bundle:7] (null on hba1c) — partial conflict
- Severity 4 null vs positive: Kim 2024 [bundle:10] vs Hu 2021 [bundle:9]; Hu 2021 [bundle:9] (positive on body mass index) vs Kim 2024 [bundle:10] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Malin 2026b [bundle:11] vs Malin 2026a [bundle:6]; Malin 2026a [bundle:6] (positive on body weight) vs Malin 2026b [bundle:11] (null on body weight) — partial conflict

## References

- **Schiapaccassa 2019.** _30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study._ Diabetology & Metabolic Syndrome, 2019. DOI: 10.1186/s13098-019-0466-2 PMID: 31462933.
- **Guo 2026.** _HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin._ JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.15622 PMID: 42234428.
- **Park 2024.** _Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial._ Diabetes & Metabolism Journal, 2024. DOI: 10.4093/dmj.2023.0259 PMID: 38650099.
- **Qin 2025.** _Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis._ Medicine, 2025. DOI: 10.1097/MD.0000000000041061 PMID: 39792745.
- **Sahay 2026.** _Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70778 PMID: 42070788.
- **Mohan 2026.** _Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study._ Journal of Diabetes, 2026. DOI: 10.1111/1753-0407.70217 PMID: 41979234.
- **Malin 2026a.** _Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70478 PMID: 41532329.
- **Han 2020.** _Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial._ Journal of Clinical Medicine, 2020. DOI: 10.3390/jcm9010259 PMID: 31963648.
- **Mueller 2021.** _Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial._ Diabetes Care, 2021. DOI: 10.2337/dc20-2257 PMID: 34006565.
- **Hu 2021.** _Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial._ Nutrients, 2021. DOI: 10.3390/nu13082673 PMID: 34444833.
- **Kim 2024.** _A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)._ Journal of Diabetes Research, 2024. DOI: 10.1155/2024/8915591 PMID: 38223523.
- **Malin 2026b.** _Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for Metabolic Syndrome._ The Journal of Clinical Hypertension, 2026. DOI: 10.1111/jch.70215 PMID: 41796987.
- **Marcelo-Calvo 2026.** _Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial._ eClinicalMedicine, 2026. DOI: 10.1016/j.eclinm.2026.103874 PMID: 42023167.
- **Iraji 2026.** _Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma._ Journal of Cosmetic Dermatology, 2026. DOI: 10.1111/jocd.70983
- **Guo 2021.** _Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus._ Frontiers in Endocrinology, 2021. DOI: 10.3389/fendo.2021.712200 PMID: 34659110.
- **Kumari 2026.** _Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus._ Cureus, 2026. DOI: 10.7759/cureus.101227 PMID: 41669572.
- **Agarwal 2026.** _Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial._ Indian Journal of Endocrinology and Metabolism, 2026. DOI: 10.4103/ijem.ijem_635_25 PMID: 41918604.
- **Li 2025.** _Medication count, including statin or metformin use, is not associated with influenza vaccine responses in older adults._ Vaccine, 2025. DOI: 10.1016/j.vaccine.2025.127913 PMID: 41167013.
- **Abed 2024.** _Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee osteoarthritis: randomized clinical trial._ Journal of Orthopaedic Surgery and Research, 2024. DOI: 10.1186/s13018-024-05120-0 PMID: 39456024.
- **Maio 2026.** _Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study._ Neuro-Oncology Advances, 2026. DOI: 10.1093/noajnl/vdag041 PMID: 41788737.
- **Shadyab 2025.** _Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2025. DOI: 10.1093/gerona/glaf095 PMID: 40388602.
- **Behbudi 2025.** _Effect of Metformin on Clinical Course of Non-Diabetic Patients with Ischemic Stroke._ Galen Medical Journal, 2025. DOI: 10.31661/gmj.v14i.4049 PMID: 42038850.
- **Inzucchi 2020.** _MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D._ Journal of the Endocrine Society, 2020. DOI: 10.1210/jendso/bvaa046.414
- **Shen 2026.** _Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70598 PMID: 41755790.
- **R 2026.** _Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape._ Annals of Neurosciences, 2026. DOI: 10.1177/09727531261421807 PMID: 41930282.
- **Bilusic 2026.** _The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients._ EMBO Molecular Medicine, 2026. DOI: 10.1038/s44321-026-00408-6 PMID: 41942753.
- **Tavabi 2021.** _A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2991
- **Espinoza 2022.** _CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES._ Innovation in Aging, 2022. DOI: 10.1093/geroni/igac059.2117
- **Espinoza 2025a.** _A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1648
- **Espinoza 2025b.** _METFORMIN TO TARGET FRAILTY IN OLDER ADULTS._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1104
- **Orchard 2021.** _Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2339
- **Effects of Metformin on Biomarkers 2026.** _3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial._ Age and Ageing, 2026. DOI: 10.1093/ageing/afaf368.097
- **Comparison of Efficacy and Safety 2022.** _Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial._ National Journal of Physiology, Pharmacy and Pharmacology, 2022. DOI: 10.5455/njppp.2022.12.062851202217862022

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "30a95fab-c3d5-4c14-ba3b-52bcacfac4ae",
  "title": "Research Synthesis: Metformin Intervention Metformin Treatment Effects"
}